Harvard Bioscience (HBIO) - EV/EBITDA Multiple
The Harvard Bioscience (HBIO) price chart on the GURU.Markets platform with the 13.18 indicator allows for an assessment of the business's dependence on the demand for high-precision biomedical equipment and order volumes from pharmaceutical behemoths. The company generates revenue through the sale of cell analysis systems and dosing pumps for laboratories. The brand's impeccable reputation among scientists and universities makes the manufacturer's position highly resilient to market volatility.
Analytical breakdowns for Harvard Bioscience Inc. (HBIO)
- stock price and consensus target price:
- market capitalization indicators:
- issuer book value statistics:
- company liabilities and liquidity data:
Total Debt to Equity Ratio Harvard Bioscience|HBIO - Long-Term Loans to Capital Ratio|Short-Term Debt to Equity Harvard Bioscience|HBIO - Aggregate Debt Obligations|Debt to Book Value Harvard Bioscience, Inc.|HBIO - Company Long-Term Debts|Company Short-Term Debt Harvard Bioscience|Quick Ratio harvardbioscience.com
- business earnings and investment ratios data:
HBIO - Company Net Income|Expected Profit Harvard Bioscience|HBIO - Price to Earnings Multiple|Projected Price to Earnings Harvard Bioscience, Inc.|HBIO - Company Value to Earnings Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Harvard Bioscience, Inc.|HBIO - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Harvard Bioscience|HBIO - Earnings per share for the trailing year|Quarterly EPS earnings growth harvardbioscience.com|HBIO - Earnings growth in current year|Net earnings per share growth forecast for next year Harvard Bioscience
Summary company analysis:Harvard Bioscience, Inc. (HBIO)
For the conservative investor, this ratio serves as a key valuation metric, combining market capitalization and net debt relative to earnings before interest, taxes, depreciation, and amortization. By analyzing the EV/EBITDA trajectory of Harvard Bioscience (HBIO), one can assess the stability of HBIO: the low cyclicality of demand for laboratory equipment smooths the volatility of this multiple, confirming the fundamental reliability of the business even under a significant debt load.
Competitors of Harvard Bioscience
Intuitive Surgical Inc - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation DHR|Becton Dickinson & Co - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio steris.com STE|West Pharmaceutical Services, Inc. (WST) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation BAX|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Masimo Personal Health|Stevanato Group Corp (STVN) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio TFX (Teleflex Incorporated)|Enterprise Value to Operating Income Before Depreciation Ratio MMSI|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Envista NVST|Business Value to Operating Income Before Depreciation ICUI|XRAY: Enterprise Value to EBITDA Ratio|LMAT - EV/EBITDA Multiple|AtriCure, Inc. (ATRC) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio staar.com|NAGE (ChromaDex Corp.) - EV/EBITDA Multiple|Company Value to EBITDA ZimVie Inc ZIMV|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization AngioDynamics Corp (ANGO)|Cerus Inc - Enterprise Value to Operating Income Before Depreciation|Alpha Teknova, Inc. - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio MGRM (monogramorthopedics.com)|STSS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio InfuSystem Holdings INFU|UTMD: EV/EBITDA Multiple|KORU Medical - Business Value to Operating Income Before Depreciation|NYXH (Nyxoah S.A.) - EV/EBITDA Multiple|EV/EBITDA Multiple microbotmedical.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pro-Dex (PDEX)|ZTEK (Zentek Ltd) - Business Value to Operating Income Before Depreciation|Elutia Corp - Enterprise Value to EBITDA Ratio|Milestone Scientific Corporation - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|NEXGEL, Inc. - EV/EBITDA Multiple|RVP - EV/EBITDA Multiple|Femasys (FEMY) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Meihua Medical Technologies Co., Ltd. - Business Value to Operating Income Before Depreciation|POAI (Predictive Oncology Inc) - EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation CJMB (Callan JMB Corp)|Enterprise Value to EBITDA Ratio ATRI (Atrion Corporation)|NURO (neurometrix.com) - Business Value to Operating Income Before Depreciation
